drugset / Trial / NCT04693429

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+

NCT04693429

Phase 1 Completed 22 enrolled Laboratorios Sophia S.A de C.V.
NaSingle-groupOpen-labelOther

Summary

Clinical phase I, controlled, non comparative, open, single center study evaluating the safety and tolerability of ophthalmic solution PRO-172 when applied on the ocular surface of healthy volunteers.

Timeline

Start
2020-09-24
Primary completion
2020-11-27
Completion
2020-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bepotastine Small molecule 1.5 % Topical

Indications

No indication recorded.